E Keppra Tablet Approved in Japan for Pediatric Epilepsy

barbara.lempert

Antiepileptic Drug E ® in for (Partial-Onset Seizures) occurs most frequently in infants and elderly, and it is estimated that there are at least 150,000 patients in Japan.
Effective antiepileptic drugs which can be safely continued for an extended period of time are much needed, as children with epilepsy and their families are often worried about seizures during school time, how the repeated seizures may affect pediatric patients’ brain development, and adverse drug reactions such as sleepiness that may interfere with studying.
E Keppra® is approved and prescribed for the treatment of pediatric epilepsy in over 80 countries and regions around the world. E Keppra® is an antiepileptic drug which does not share the mechanism of action with any conventional antiepileptic drugs, and therefore the additional indication offers a new treatment option for pediatric patients and contributes to pharmacotherapy for epilepsy in these patients.
Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo, Japan; president and representative director: Taro Iwamoto) and UCB Japan Co., Ltd. (head office: Tokyo, Japan; president and representative director: Joel Peterson) today obtained regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® 250 mg and 500 mg Tablets (levetiracetam) as adjunctive therapy in combination with other antiepileptic drugs in the treatment of “partial-onset seizures in pediatric patients with epilepsy aged four years and older.”

Epilepsy may occur at any age, but it occurs most frequently in infants and the elderly. Pediatric as well as adult patient needs for antiepileptic drug treatments have not yet been fully met and this new pediatric indication was developed in response to strong requests from the medical community and other concerned parties. Patient quality of life, especially in pediatric patients, is affected if…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS